Nifedipine pharmacokinetics and plasma levels in the management of preterm labor.
The aim of this study was to determine if the dose regimen of nifedipine used for tocolysis was effective to achieve uterine quietness, and at which plasma concentration levels this tocolysis was achieved to optimize our dose regimen of nifedipine. In women with preterm labor, nifedipine was administered orally to achieve uterine quietness to prevent preterm birth. Patients (n = 5) were administered 10 mg nifedipine capsules (Adalat capsules, Bayer AG) orally every 15 minutes up to 40 mg in the first hour, and were subsequently given 1 tablet of 20 mg nifedipine slow release (Adalat retard, Bayer AG) t = 90 min. Plasma levels of nifedipine were measured at regular intervals during the first 4 hours after starting tocolysis. In all 5 patients tocolysis was achieved with nifedipine. Peak plasma concentration of nifedipine was 127.2 +/- 44 ng/mL at 1.2 +/- 0.1 hours. Mean plasma concentrations of nifedipine was 67.4 +/- 28.4 ng/mL. In all patients, tocolysis was achieved during the 4 hours of blood sampling. There were no adverse hemodynamic side effects seen before and after starting tocolysis with nifedipine. Initial dose regimen of 4 times 10 mg nifedipine capsule orally in the first hour, followed by 20 mg slow release nifedipine at t = 90 min is effective in achieving tocolysis in women with preterm labor. In steady state, the mean nifedipine plasma concentration to achieve tocolysis is about the half of that measured after initial tocolysis. Use of nifedipine for preterm labor was not associated with any adverse hemodynamic side effects.
Papatsonis
Dimitri N M
DN
Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The Netherlands. hoog.pap@wxs.nl
Bos
Jacqueline M
JM
van Geijn
Herman P
HP
Lok
Christianne A R
CA
Dekker
Guus A
GA
D000328:Adult; D001794:Blood Pressure; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D009543:Nifedipine / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics*; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D011247:Pregnancy; D011674:Pulse; D015149:Tocolytic Agents / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics*
D003692:Delayed-Action Preparations; D015149:Tocolytic Agents; D009543:Nifedipine